🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: indacaterol and glycopyrronium bromide (QVA149)

Found 24 matching trials

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

PHASE3

This study will assess the efficacy, safety and tolerability of indacaterol...

Status

Completed

Location

Novartis Investigative Site

Start Date

2012-12

Trial ID

NCT01712516

Treatments Being Tested

QVA149 QAB149 NVA237 Placebo

Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen

PHASE4

The main goal of this study is to evaluate the efficacy and safety of glyco...

Status

Completed

Location

Novartis Investigative Site

Start Date

2014-02-14

Trial ID

NCT01985334

Treatments Being Tested

Glycopyrronium SABA LABA Indacaterol maleate and glycopyrronium bromide LAMA SAMA ICS

A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

The purpose of this study was to determine whether a fixed dose combination...

Status

Completed

Location

Novartis Investigative Site

Start Date

2014-11-30

Trial ID

NCT02233543

Treatments Being Tested

QVA149 QVA149 Placebo

QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The purpose of this study is to compare the efficacy and safety/tolerabilit...

Status

Completed

Location

Novartis Investigative Site

Start Date

2011-03

Trial ID

NCT01315249

Treatments Being Tested

indacaterol and glycopyrronium (QVA149)Placebo to fluticasone/salmeterol fluticasone/salmeterol Placebo to indacaterol and glycopyrronium (QVA149)

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

PHASE3

This study is designed to assess the effect of once-daily QVA149 on COPD ex...

Status

Completed

Location

Novartis Investigative Site

Start Date

2010-04

Trial ID

NCT01120691

Treatments Being Tested

QVA149 NVA237 tiotropium Salbutamol/albuterol

Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

PHASE4

This study will evaluate the efficacy and safety of QVA149 (110/50 μg o.d.)...

Status

Completed

Location

Novartis Investigative Site

Start Date

2015-11-20

Trial ID

NCT02603393

Treatments Being Tested

QVA149 Tiotropium Salmeterol/fluticasone

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

PHASE3

The study will assess the long-term safety of the fixed combination product...

Status

Completed

Location

Novartis Investigative Site

Start Date

2012-10

Trial ID

NCT01610037

Treatments Being Tested

QVA149 Tiotropium placebo

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

PHASE3

The purpose of this study is to demonstrate that the efficacy of the combin...

Status

Completed

Location

Novartis Investigative Site

Start Date

2015-07-27

Trial ID

NCT02487498

Treatments Being Tested

QVA149 Umeclidinium/vilanterol Placebo (umeclidinium/vilanterol )Placebo (QVA149)

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

PHASE3

This study is to assess the safety and tolerability of two different doses ...

Status

Completed

Location

Novartis Investigative Site

Start Date

2012-10

Trial ID

NCT01682863

Treatments Being Tested

QVA149 QVA149 QAB149 Placebo

Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The study assessed the safety and efficacy of the fixed combination product...

Status

Completed

Location

Novartis Investigative Site

Start Date

2012-05

Trial ID

NCT01529632

Treatments Being Tested

QVA149 NVA237 QAB149 Placebo

Previous Next